Cargando…
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
AIMS: To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet formulation of a glucagon‐like peptide‐1 receptor agonist. MATERIALS AND METHODS: PIONEER 6 is a multinational, randomized, placebo‐controlled, double‐blind trial in patients with type 2 diabetes at high risk of CV...
Autores principales: | Bain, Stephen C., Mosenzon, Ofri, Arechavaleta, Rosario, Bogdański, Pawel, Comlekci, Abdurrahman, Consoli, Agostino, Deerochanawong, Chaicharn, Dungan, Kathleen, Faingold, Maria C., Farkouh, Michael E., Franco, Denise R., Gram, Jeppe, Guja, Cristian, Joshi, Pankaj, Malek, Rachid, Merino‐Torres, Juan F., Nauck, Michael A., Pedersen, Sue D., Sheu, Wayne H. ‐H., Silver, Robert J., Tack, Cees J., Tandon, Nikhil, Jeppesen, Ole K., Strange, Mette, Thomsen, Mette, Husain, Mansoor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587508/ https://www.ncbi.nlm.nih.gov/pubmed/30284349 http://dx.doi.org/10.1111/dom.13553 |
Ejemplares similares
-
Oral Semaglutide Reduces HbA(1c) and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses
por: Pratley, Richard E., et al.
Publicado: (2021) -
Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials
por: Mosenzon, Ofri, et al.
Publicado: (2022) -
Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs
por: Cherney, David Z.I., et al.
Publicado: (2022) -
Abstract 25: Glycemic variability of oral semaglutide versus empagliflozin: A post hoc analysis of PIONEER 2
por: Shabeer, D, et al.
Publicado: (2022) -
Abstract 15: Glycemic and body weight responses to oral semaglutide in the PIONEER trial program
por: Kumar, K B Sharan, et al.
Publicado: (2022)